Inhibikase Therapeutics Stock Last Dividend Paid
| IKT Stock | USD 2.96 0.24 7.50% |
Inhibikase Therapeutics fundamentals help investors to digest information that contributes to Inhibikase Therapeutics' financial success or failures. It also enables traders to predict the movement of Inhibikase Stock. The fundamental analysis module provides a way to measure Inhibikase Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Inhibikase Therapeutics stock.
Inhibikase | Last Dividend Paid |
Inhibikase Therapeutics Company Last Dividend Paid Analysis
Inhibikase Therapeutics' Last Dividend Paid refers to dividend per share(DPS) paid to the shareholder the last time dividends were issued by a company. In its conventional sense, dividends refer to the distribution of some of a company's net earnings or capital gains decided by the board of directors.
More About Last Dividend Paid | All Equity Analysis
Last Dividend | = | Last Profit Distribution AmountTotal Shares |
Inhibikase Last Dividend Paid Driver Correlations
Understanding the fundamental principles of building solid financial models for Inhibikase Therapeutics is extremely important. It helps to project a fair market value of Inhibikase Stock properly, considering its historical fundamentals such as Last Dividend Paid. Since Inhibikase Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Inhibikase Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Inhibikase Therapeutics' interrelated accounts and indicators.
Click cells to compare fundamentals
Many stable companies today pay out dividends to their shareholders in the form of the income distribution, but high-growth firms rarely offer dividends because all of their earnings are reinvested back to the business.
| Competition |
Based on the recorded statements, Inhibikase Therapeutics has a Last Dividend Paid of 0.0. This indicator is about the same for the Biotechnology average (which is currently at 0.0) sector and about the same as Health Care (which currently averages 0.0) industry. This indicator is about the same for all United States stocks average (which is currently at 0.0).
Inhibikase Therapeutics Current Valuation Drivers
We derive many important indicators used in calculating different scores of Inhibikase Therapeutics from analyzing Inhibikase Therapeutics' financial statements. These drivers represent accounts that assess Inhibikase Therapeutics' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Inhibikase Therapeutics' important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Enterprise Value | 102.5M | 55.7M | (13.7M) | (1.8M) | (2.0M) | (1.9M) |
Inhibikase Therapeutics ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Inhibikase Therapeutics' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Inhibikase Therapeutics' managers, analysts, and investors.Environmental | Governance | Social |
Inhibikase Fundamentals
| Return On Equity | -1.5 | ||||
| Return On Asset | -0.76 | ||||
| Operating Margin | (238.85) % | ||||
| Current Valuation | 211.58 M | ||||
| Shares Outstanding | 67.19 M | ||||
| Shares Owned By Insiders | 10.46 % | ||||
| Shares Owned By Institutions | 11.62 % | ||||
| Number Of Shares Shorted | 287.66 K | ||||
| Price To Book | 26.46 X | ||||
| Price To Sales | 2,702 X | ||||
| Revenue | 260.5 K | ||||
| Gross Profit | (8.26 M) | ||||
| EBITDA | (19.91 M) | ||||
| Net Income | (19.03 M) | ||||
| Cash And Equivalents | 32.21 M | ||||
| Cash Per Share | 1.28 X | ||||
| Total Debt | 622 K | ||||
| Debt To Equity | 0.01 % | ||||
| Current Ratio | 7.56 X | ||||
| Book Value Per Share | 1.77 X | ||||
| Cash Flow From Operations | (18.09 M) | ||||
| Short Ratio | 0.17 X | ||||
| Earnings Per Share | (3.12) X | ||||
| Target Price | 7.0 | ||||
| Beta | 1.12 | ||||
| Market Capitalization | 215.02 M | ||||
| Total Asset | 14.51 M | ||||
| Retained Earnings | (66.9 M) | ||||
| Working Capital | 10.77 M | ||||
| Net Asset | 14.51 M |
About Inhibikase Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Inhibikase Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Inhibikase Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Inhibikase Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Inhibikase Stock Analysis
When running Inhibikase Therapeutics' price analysis, check to measure Inhibikase Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Inhibikase Therapeutics is operating at the current time. Most of Inhibikase Therapeutics' value examination focuses on studying past and present price action to predict the probability of Inhibikase Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Inhibikase Therapeutics' price. Additionally, you may evaluate how the addition of Inhibikase Therapeutics to your portfolios can decrease your overall portfolio volatility.